Rosiden

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rosiden

Quick Facts about Rosiden

Property Description
Active ingredient Piroxicam
Form Capsule, Tablet, Suppository, Gel, Solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Relief of pain and inflammation
Origin Synthetic compound (Oxicam derivative)

What Type of Medicine is Rosiden and Its Classification?

Rosiden is a pharmaceutical preparation containing the active ingredient Piroxicam, which is scientifically classified as a potent Nonsteroidal Anti-inflammatory Drug (NSAID). This high-level designation places the medicine among agents recognized for managing the symptoms of inflammation and pain.

Piroxicam is a synthetic compound chemically categorized as an Oxicam derivative, distinguishing it structurally from other common NSAID categories. The drug is utilized as a single-ingredient product, and its long half-life is a key feature that allows for sustained therapeutic action compared to many shorter-acting alternatives.

Piroxicam's Core Composition and Available Forms

The therapeutic effect of Rosiden is derived solely from the Piroxicam molecule, the core anti-inflammatory agent it contains. This active ingredient is compounded into several major drug forms to facilitate various methods of application based on the required route of administration.

These forms include Capsule and Tablet for Oral use, Suppository for Rectal use, and local preparations like the Gel and Solution for Topical administration. The availability of these multiple forms provides flexibility in delivery, allowing for either localized application or a widespread systemic action. Within the context of NSAID pharmacology, the application of Piroxicam is intended to reduce localized symptoms.

General Purpose and Primary Therapeutic Benefit

The general purpose of Rosiden is to alleviate the symptoms of pain and inflammation associated with musculoskeletal conditions. Its primary therapeutic benefit lies in its action as a potent analgesic agent and anti-inflammatory agent.

This effect is achieved by interrupting the synthesis of prostaglandins, which are the natural messengers that propagate signals for pain and swelling in the body. By suppressing the production of these mediators, Rosiden helps to reduce tenderness and discomfort, a mechanism intended to support a patient's general mobility and comfort.

Regulatory References

  1. NIH MedlinePlus Drug Information

What side effects are possible with Rosiden?

Possible Side Effects and Safety Information

The safety profile of Rosiden (Piroxicam) is structured around risks that are characteristic of its classification as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official regulatory documents categorize adverse reactions based on the body system affected and their reported frequency.

Adverse Reaction Scope

Safety Element Regulatory Statement
Key adverse reaction categories NSAID-class effects primarily affecting the Gastrointestinal system, Cardiovascular system, and Renal system, and Severe Cutaneous reactions.
Frequency classification (incidence >2%) Most Common effects reported in clinical trials (incidence ge 2%) include nausea, constipation, flatulence, abdominal pain, diarrhea, headache, dizziness, edema, and rash.
System-organ classes involved Gastrointestinal Disorders (e.g., bleeding, ulceration), Cardiac/Vascular Disorders (e.g., heart attack, stroke), Renal and Urinary Disorders (e.g., renal toxicity), and Skin and Subcutaneous Tissue Disorders (e.g., severe skin reactions).
Serious adverse reactions Serious Cardiovascular Thrombotic Events (Myocardial Infarction and Stroke), Serious Gastrointestinal Adverse Events (Bleeding, Ulceration, and Perforation), Severe Hepatic Reactions, and Serious Skin Reactions (e.g., Stevens-Johnson syndrome) are explicitly documented as potential risks.
Population-specific safety considerations Older Adults (Geriatric Population) have a greater risk for serious Gastrointestinal events. Use is restricted near the end of pregnancy due to the risk of premature closure of the fetal ductus arteriosus.
Dose- or exposure-related patterns The risk of serious Cardiovascular Thrombotic Events and Gastrointestinal Events may increase with the duration of use. The highest risk for serious Skin Reactions is typically within the first few weeks to the first month of treatment.

Safety-Related Restrictions and Context

Rosiden is contraindicated for the treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft ( CABG) surgery. It is also contraindicated in patients with a history of allergic-type reactions (such as asthma or urticaria) after taking aspirin or other NSAIDs. Use should generally be avoided in patients with advanced renal disease.

This official safety information structures the risk profile by classifying the medicine's major potential concerns as systemic and time-dependent, highlighting the potential for serious outcomes that increase with the length of use, particularly in susceptible populations.

Overdose and Emergency Response

The official regulatory profile for Rosiden (Piroxicam) overdose defines a range of potentially severe, life-threatening outcomes. Documented manifestations may affect multiple systems, including severe headache, confusion, agitation, and convulsions within the central nervous system, alongside nausea, vomiting, and diarrhea. Systemic complications include hypotension (shock), little to no urine production indicating renal impact, and the risk of fatal gastrointestinal bleeding or perforation. Overdose risk is associated with exposure exceeding the therapeutic regimen, with elderly patients noted in labeling as having an increased risk of serious adverse effects.

Immediate medical attention is the mandated emergency action, requiring contact with emergency services or the Poison Help hotline upon suspicion or manifestation of any overdose symptoms. Urgent medical help must not be delayed. As no specific antidote is documented in official sources, management is strictly symptomatic and supportive. This involves procedures such as administering activated charcoal and intravenous fluids, along with continuous monitoring of vital signs, heart function via ECG, and blood and urine tests in a supervised setting.

Therapeutic Uses of Rosiden

What Rosiden treats: main uses and benefits


Rosiden is applied across domains where additional symptomatic support is needed, primarily for conditions involving inflammatory processes. This medication may be used in conditions characterized by chronic, persistent inflammation, such as Osteoarthritis and Rheumatoid Arthritis. It is relevant for managing symptom clusters that create noticeable interference with daily stability.

This medicine is considered relevant for addressing symptoms associated with Ankylosing Spondylitis, acute gout, acute musculoskeletal disorders, and primary dysmenorrhea. It is relevant for managing pronounced symptomatic manifestations when symptoms become more noticeable.

“It is relevant for managing pronounced symptomatic manifestations.”

This symptomatic assistance contributes to easing discomfort during challenging periods of episodic pain and cramping, offering support that contributes to easing the overall symptom load.


Quick Fact: Focus on Inflammatory Symptoms

Regulatory References

  1. DailyMed official information on Piroxicam

Eligibility and Restrictions for Use

Rosiden (Piroxicam) eligibility is defined by official regulatory documentation, which establishes its use for the adult population only. Use is strictly limited or entirely prohibited in patient groups with specific comorbidities or physiological states, particularly due to known cardiovascular and gastrointestinal risks associated with the Nonsteroidal Anti-inflammatory Drug (NSAID) class.

Populations Who Must Not Use Rosiden

The medicine is strictly contraindicated in patients with:

  • Known hypersensitivity to Piroxicam, Aspirin, or any other NSAID (e.g., aspirin-sensitive asthma).
  • History of active peptic ulceration, gastrointestinal bleeding, or perforation.
  • Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Age and Physiological Restrictions

Population Regulatory Status
Pediatric Population (Under 18) Safety and efficacy not established; not approved for use.
Pregnancy Avoid use starting at 30 weeks gestation (third trimester).
Lactation Not recommended for use in nursing mothers.

Condition-Based Limitations

Regulatory documents mandate that use be avoided in patients with advanced renal disease, severe heart failure, or those who have recently experienced a Myocardial Infarction (MI). Patients with uncontrolled hypertension or who are CYP2C9 poor metabolizers may require special clinical monitoring.

What should I know about interactions with other medicines?

Rosiden Interactions with other medicines and products

Rosiden (Piroxicam) has a defined interaction profile based on official regulatory documentation, primarily involving agents that affect bleeding risk or renal function.

Interaction Classifications and Restrictions

The regulatory profile formally restricts co-administration with several medicinal product categories:

  • Contraindicated Combinations: Rosiden is restricted for use in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery and must be avoided with other systemic NSAIDs and oral anticoagulants. Use with analgesic doses of Aspirin is not generally recommended.
  • Systemic Exposure Modification: Piroxicam can elevate the plasma concentrations of certain co-administered drugs, including Lithium and Digoxin, due to decreased renal elimination of these substances. Piroxicam itself is primarily metabolized via CYP2C9, and individuals identified as poor metabolizers of this enzyme may exhibit higher systemic levels.
  • Pharmacodynamic Antagonism: Co-administration with ACE Inhibitors, ARBs, or Diuretics may diminish the therapeutic effect of these medicines. This interaction risk is specifically noted to be heightened in elderly, volume depleted, or renally impaired patients.
  • Additive Risk: Combining Rosiden with other medicines that interfere with hemostasis, such as SSRIs or antiplatelet agents, increases the risk of bleeding. The use of alcohol is documented as a risk factor that also increases the risk of serious gastrointestinal events.

Mechanism of Action

Molecular Targets: Inhibition of Prostanoid Synthesis

The primary mechanism of Rosiden (Piroxicam) involves acting as a non-selective reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically targeting both the COX-1 and COX-2 isoforms. This molecular action directly halts the first step in the conversion of arachidonic acid into prostaglandins and other related signaling mediators.

Mechanistic Cascade: Dampening Inflammatory Signaling

By suppressing the synthesis of pro-inflammatory mediators like Prostaglandin E2 (PGE2), the drug engages a physiological cascade that attenuates the signaling cascades associated with localized inflammation and nociception. This systemic reduction of chemical messengers decreases the chemical sensitization of nociceptors (pain-sensing nerves) and modulates the vasodilation observed in affected tissues.

Functional Limitations of Non-Selective Action

The mechanism of Piroxicam carries a functional constraint due to its non-selective inhibition, meaning it cannot distinguish between the inflammatory COX-2 and the homeostatic COX-1 enzyme. This simultaneous inhibition affects the COX-1 driven synthesis of constitutive prostaglandins, which participate in the maintenance of local physiological processes, including gastric mucosal function.

Dosage and Administration Information

How Rosiden Is Used

The administration of Rosiden (Piroxicam) is structured according to clinical guidelines, defining the appropriate route, dose, and frequency based on the condition being addressed. The medicine is primarily available for Oral administration in Capsule or Tablet forms, but it is also approved for Rectal and Topical application.

Official Dosing and Frequency

The standard protocol for long-term use in chronic conditions, such as Osteoarthritis and Rheumatoid Arthritis, establishes a daily systemic dose of 20 mg taken once daily. This dose is the maximum recommended for chronic maintenance. For short-term acute symptomatic treatment, such as acute gout or acute musculoskeletal disorders, the regimen typically begins with a higher initial dose of 40 mg daily for the first one to two days, followed by a reduction to 20 mg daily for the remainder of the course. Treatment for acute conditions is generally time-limited, often lasting between 4 and 14 days.

Administration Context and Adjustments

To ensure proper intake, Rosiden should be consumed with or immediately following food or with an adequate amount of water. This instruction is tied to the prescribed method of use. The principle of using the lowest effective dosage for the shortest duration is a standard requirement for its application. The dosage requires careful individual assessment for older adults and patients with known impaired liver or kidney function, including considering a dose reduction for those known to be CYP2C9 poor metabolizers.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rosiden

The following overview describes the research landscape for Rosiden (Piroxicam) based on clinical evaluation studies and regulatory summaries. This information details what researchers have examined and where the current evidence remains uncertain.


Evidence for Symptomatic Support in Osteoarthritis (OA)

Research exploring the use of Rosiden in adults with Osteoarthritis (OA), a condition marked by functional limitations and outcomes related to physical discomfort, primarily consists of Randomized Controlled Trials (RCTs) and systematic reviews. These trials examined short-term symptom changes, often comparing Rosiden against a placebo or other anti-inflammatory medicines. Findings describe patterns observed in the studies over follow-up periods that generally lasted from a few weeks up to several months. Follow-up durations were limited in many controlled trials, meaning that long-term effects are not fully established regarding the sustained nature of observed symptomatic patterns.


Evidence for Managing Rheumatoid Arthritis (RA) Symptoms

For Rheumatoid Arthritis (RA), a condition characterized by fluctuating or episodic manifestations, Rosiden was studied for symptom measurements related to inflammatory states. The research base includes controlled clinical trials which focused on outcomes linked to inflammatory or irritative states, monitoring measurements such as the number of tender and swollen joints, and the length of morning stiffness. Studies report how symptoms evolved in the observed populations during the measured time intervals. As with OA, there is limited information for long-term outcomes regarding the effects of using the medicine continually for many years.


What Research Gaps and Uncertainties Exist

Current evidence highlights areas where certainty remains low or where more research is ongoing. A significant limitation is that the long-term effects are not fully established from the available controlled research. The comparative evidence is lacking for some of the newer treatment options currently available. Finally, for some indications, the results apply only to the populations studied, meaning that subgroup findings are uncertain when applied to patients with unique or complex co-existing conditions that were not represented in the trials.

Key Studies & References

  1. Efficacy and safety of piroxicam revisited: a global meta-analysis of randomised clinical trials

Frequently Asked Questions (FAQ)

Common questions about Rosiden (FAQ)

Q: What if I'm already taking supplements; could they interact with Rosiden?

A: Regulatory information notes that combining Rosiden with any substance that increases the risk of bleeding or affects the kidneys may lead to adverse events. Because of this, it is advisable to discuss all supplements, vitamins, and herbal products with a healthcare provider before starting Rosiden.

Q: Do I need a special monitoring or blood tests while on Rosiden?

A: According to official product information, regular clinical monitoring is typically indicated for patients receiving long-term Rosiden therapy. This often includes periodic assessments, such as blood cell counts and checking how well the kidneys and liver are functioning. This monitoring helps ensure that the body is responding appropriately to the medication.

Q: What does the drug classification of Rosiden mean for me?

A: Rosiden is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), meaning its primary purpose is to reduce pain and inflammation. Official documents note that this drug class is associated with specific potential risks. These risks primarily involve the gastrointestinal system (stomach and bowels) and the cardiovascular system (heart).

Q: Why are there so many warnings listed in the Rosiden leaflet?

A: Official regulatory documents state that the warnings associated with Rosiden are characteristic of the entire Nonsteroidal Anti-inflammatory Drug (NSAID) class. These comprehensive warnings are included to ensure patients are aware of the potential systemic risks, particularly concerning the cardiovascular and gastrointestinal systems.

Q: Can Rosiden affect my blood pressure?

A: Official labeling describes that Rosiden can be associated with the development of new hypertension, or high blood pressure. It may also worsen blood pressure in those who already have the condition. Regulatory standards suggest that blood pressure be monitored closely while taking the medication.

Q: Are there different strengths of Rosiden tablets available?

A: The official product information specifies that Rosiden is available in multiple formulations to facilitate various uses. The common oral dosage forms typically include 10 mg and 20 mg capsule or tablet strengths.

Q: Does the time of day matter when taking Rosiden?

A: Because Rosiden has a long half-life, it is designed to be taken only once per day. To maintain a consistent level of the medicine in the body, it is generally recommended that the dose be consumed around the same time each day. The official regimen does not typically specify morning or evening intake.

Q: Why is Rosiden sometimes prescribed for long periods?

A: Rosiden is prescribed for chronic conditions like Rheumatoid Arthritis and Osteoarthritis, which require sustained symptom management. Official information confirms the medicine has a long half-life, meaning it stays active in the body for an extended time. This characteristic supports its use in long-term treatment protocols.

Q: What is the definition of 'contraindication' for Rosiden?

A: A contraindication is a concept described in official documents as a condition where a treatment must be strictly avoided. For Rosiden, these are situations where taking the medicine carries a high and unacceptable risk of causing harm to the patient.

Q: How long does it typically take to notice the effects of Rosiden?

A: The onset of action is variable, though the drug's peak concentration in the blood is often reached within a few hours of intake. However, official studies indicate that it may take 7 to 12 days of continuous use to reach the necessary sustained level in the body. The full therapeutic benefit is generally observed after this sustained period.

Q: What happens if I forget to take a dose of Rosiden?

A: Official patient leaflets contain instructions that if a dose is missed, it may be taken as soon as recalled. If the time for the next dose is near, the instruction is that the missed dose be skipped. The leaflets note that taking a double dose to make up for a missed one is not advised.

Q: Is it true that Rosiden can cause dry mouth?

A: Regulatory documents indicate that dry mouth has been reported as an adverse reaction during clinical experience with Rosiden. This is considered a possible side effect, though it is not classified among the most common effects.

Q: Is Rosiden known to affect sleep patterns?

A: Official labeling describes that Rosiden can affect sleep patterns. Reported adverse effects include insomnia (trouble sleeping) and, conversely, drowsiness or somnolence (sleepiness).

Q: Is Rosiden a drug that can be stopped suddenly?

A: Rosiden is not typically a medication that requires a gradual reduction in dose, or tapering, before stopping. However, official documentation advises that any decision to stop the medication, especially when treating chronic conditions, be made only with the guidance of a healthcare professional.

Q: Does Rosiden have a sedative effect?

A: Yes, official product information lists somnolence and drowsiness as reported adverse reactions. This indicates that the medication has the potential to cause a mild sedative effect.

Q: Is a metallic taste in the mouth a known side effect of Rosiden?

A: Official product information includes reports of 'taste perversion' or 'dysgeusia' among its possible side effects. This described effect may manifest as an unpleasant or metallic taste in the mouth.

Q: Is it possible for Rosiden to lose its effectiveness over time?

A: Official documents advise that the continued need for Rosiden be periodically reviewed by a healthcare professional to ensure that the medication is providing sustained control of symptoms. Long-term studies examining potential loss of efficacy over many years of continuous use are not fully established.

Q: Does Rosiden carry any warnings about driving or operating machinery?

A: Official safety sections contain warnings regarding the potential for dizziness and drowsiness. Caution is advised when performing tasks that require concentration, such as driving or operating machinery.

Q: How quickly is Rosiden eliminated from the body?

A: Regulatory documents on pharmacokinetics state that Rosiden has a characteristically long half-life, which refers to the time it takes for half the drug to be eliminated. This period is reported to typically range from 30 to 60 hours in healthy adults.

Q: Do official documents mention Rosiden's effect on mental clarity?

A: Official product information reports various central nervous system (CNS) adverse effects. These include reports of confusion, depression, and nervousness, which are factors that may affect a patient's mental clarity.

Q: Is Rosiden a controlled substance?

A: Rosiden, whose active ingredient is Piroxicam, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). According to regulatory bodies, Rosiden is not classified as a controlled substance and is not subject to the scheduling regulations for controlled medications.

Q: Can I split or crush my Rosiden tablets?

A: Official instructions state that Rosiden capsules and tablets should generally be consumed whole. Unless the tablet is specifically scored to allow for splitting, physical manipulation of the dosage form, such as crushing or splitting, is not recommended by the official labeling.

Q: Does Rosiden interact with birth control pills?

A: Regulatory information indicates that Rosiden is not known to significantly reduce the effectiveness of hormonal contraceptives. Since drug interaction profiles are complex, consultation with a healthcare provider is important for confirming this information.

Q: What is the likelihood of gaining or losing weight while taking Rosiden?

A: Official adverse reaction sections list fluid retention, also known as edema, and changes in body weight as possible effects. The weight change is primarily linked to the body retaining extra fluid.

Q: Does Rosiden have an impact on fertility?

A: Official product information includes a regulatory statement that Rosiden, like other NSAIDs, may temporarily and reversibly impair female fertility. For this reason, official sources advise against the use of Rosiden in women who are actively trying to conceive.

Q: Are there specific symptoms that mean Rosiden is working?

A: Studies and official information define the therapeutic goal of Rosiden as the reduction of pain and symptoms related to inflammation. Evidence indicates this reduction is typically measured by outcomes such as decreased joint tenderness, reduced swelling, and shorter periods of morning stiffness.

How should Rosiden be stored and disposed of?

Storage and Disposal Requirements

Official regulatory labeling for Rosiden (Piroxicam) specifies strict conditions to maintain product stability and ensure safety.

Storage Conditions

Rosiden must be stored at controlled room temperature, which ranges from 20 C to 25 C (68 F to 77 F). The product requires protection from moisture, excessive humidity, and heat. The container must be kept tightly closed and remain in its original packaging. It is prohibited to freeze the medicine. As a mandatory safety measure, the product must be kept out of the reach and sight of children.

Disposal Instructions

Unused or expired Rosiden should not be discarded in household trash or poured into wastewater (down the sink or toilet). The recommended procedure is to utilize an official drug take-back program or consult a pharmacist or local regulatory body for proper disposal guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rosiden found in:

A-Z Index: